Document is current
Any future updates will be listed below
-
Authors
Hein, Marco Y.
Weissman, Jonathan S. https://orcid.org/0000-0003-2445-670X
-
Funding
Funding for this research was provided by:
European Molecular Biology Organization (ALTF 1193-2015)
Howard Hughes Medical Institute
- License Information
-
More Information
Article History
Received: 24 March 2021
Accepted: 17 August 2021
First Online: 25 October 2021
Competing interests
: J.S.W. has filed patent applications related to CRISPRi screening and Perturb-seq. J.S.W. consults for and holds equity in KSQ Therapeutics and Maze Therapeutics and consults for 5AM Ventures.
